To guarantee the reliability of the laboratory reports that carry out the diagnosis of Covid-19, from April, the Proficiency Testing for Molecular Biology of SARS-CoV2 will be enriched with items of different variants of the virus and the participants will be able to report the identification
Since the discovering the new SARS-CoV2 variants, experts began to discuss the ability of analytical systems in use to continue to accurately identify the presence of the virus. This discussion is due to the presence of different mutations in the virus genome and the sensitivity and effectiveness of the various genetic targets to identify them.
As a result, manufacturers of reagent kits are adapting information and laboratories are evaluating whether the analytical systems used in the routine need adjustments. To collaborate in this scenario, Controllab, a pioneer in quality control for SARS-CoV2, will enrich the Molecular Biology Proficiency Testing of SARS-CoV2 (Nasopharynx and Oropharynx).
In April, in addition to the 2 items that make up the program, another three extra items will be sent containing variants of the virus from different regions, for the detection of SARS-CoV2. The EP consists of inactivated and lyophilized cell suspension items prepared from viral isolation containing the complete SARS-CoV2 genome (Nasopharynx and Oropharynx). In it, users already report identification of genes E, RdRp, N, N1, N2, ORF1ab, S and ORF3a.
In addition to these identifications, participants who already have kits that distinguish mutations in the routine will be able to report the variant found. This initiative will assist both kit manufacturers and laboratories, demonstrating the relevance of quality control for decisions about the systems implanted in the routine.
The round will be another opportunity for the diagnostic sector to play a leading role, highlighting the reliability of analytical routines. Organizations that apply Molecular Biology using the reverse transcription polymerase chain reaction (RT-PCR) method for the detection of SARS-CoV2 are eligible to participate in the program.
Currently, there are more than 160 participating laboratories – 25% of which are from different continents – such as Europe, Asia and the Latin American region. This region includes 7 different countries, including Brazil. The profiles of the participating laboratories prove the heterogeneity of the data, contributing to a robust interlaboratory comparison program.
“This is also an opportunity for suppliers and manufacturers of diagnostic kits to demonstrate the performance and representativeness of the results of their analytical systems to the market”, informs Jéssica Gomes, Service Management supervisor.
Suppliers and manufacturers who wish to enroll their users, as well as laboratories that have not yet adhered to the EP Molecular Biology Coronavirus (SARS-CoV2), can access the program page to participate.
To learn more, access the site, contact us by email contato@controllab.com or by phone and WhatsApp (21) 97901-0310 and (21) 98036-1592.
Related news
Proficiency Testing: reliability for the analytical performance of laboratories
Far beyond the legislative obligation, Proficiency Testing is essential in the process of continuous improvement of the laboratory Looking for a new path in the day-to-day
Proficiency Testing for Research on Neutralizing Antibodies for Covid-19
A pioneer in the quality control initiatives for SARS-CoV2, Controllab – the country’s largest proficiency provider, launched in February the Proficiency Testing for Research on Neutralizing
Controllab Expands Quality Control of the Neutralizing Antibody Research to Covid-19
Aware of the movements in the diagnostic market for the exam, the company will provide Proficiency Testing for RDT/Point of Care (POC) in April In February